TT&A and JSA Advocates & Solicitors have acted on the Romsons Temasek investment, as Romsons Group Private Limited secured a strategic minority stake acquisition from Jongsong Investments Pte. Ltd., an indirect wholly owned subsidiary of Temasek Holdings (Private) Limited. The transaction also involved the sale of certain shares of Romsons by its promoter group and other shareholders to Temasek.
Introduction
Romsons Group Private Limited has secured an investment from Jongsong Investments Pte. Ltd., an indirect wholly owned subsidiary of Temasek Holdings (Private) Limited. The proposed combination entails an internal restructuring by Romsons Group and subscription to certain compulsorily convertible preference shares (CCPS) and acquisition of certain equity share capital of Romsons by Jongsong Investments.
Jongsong Investments is an investment holding company and an indirect wholly-owned subsidiary of Temasek Holdings. Romsons Group is engaged in the manufacturing and sale of medical devices, and personal care and hygiene products in India and globally, through exports. The Competition Commission of India (CCI) approved the proposed combination on 16 June 2026.
TT&A advised Romsons with relation to the investment as well as the sale of certain shares of Romsons by the promoter group and other shareholders to Temasek. JSA Advocates & Solicitors advised Temasek on this transaction.
Deal Value
The financial terms of the transaction were not disclosed.
Legal Teams Involved
TT&A — Counsel to Romsons Group
TT&A represented Romsons Group Private Limited across both the primary investment and the secondary share sale by the promoter group.
Transaction Team:
- Gautam Saha — Joint-Managing Partner
- Shivranjani Ralawata — Partner
- Nishant Singh — Managing Associate
- Eshani Agarwal — Associate
Competition Law Team:
- Sonam Mathur — Partner
- Samriddha Gooptu — Senior Associate
- Indrayani Bhadra — Associate
JSA Advocates & Solicitors — Counsel to Temasek
JSA Advocates & Solicitors advised Temasek Holdings (Private) Limited / Jongsong Investments Pte. Ltd. on this transaction. Further details of the JSA team were not disclosed.
Significance and Impact
Founded in 1952 by Ram Lal Khanna, Romsons pioneered the transition from reusable surgical equipment to single-use, disposable medical devices in India to reduce hospital infection rates. This heritage, spanning over seven decades, lends the deal considerable weight as Romsons receives its first significant round of external institutional capital.
Romsons Group has brought Temasek on board as a minority investor in a strategic private equity transaction aimed at funding the medical devices maker’s expansion in India and overseas and supporting potential acquisitions. The partnership is aimed at supporting Romsons’ expansion while strengthening its product portfolio, manufacturing capabilities, technology, and organisational processes.
Romsons said it would also assess the possibility of accessing public markets at an appropriate time, subject to its business trajectory and prevailing market conditions. The transaction is also notable for its competition law dimension: Sonam Mathur (Partner), Samriddha Gooptu (Senior Associate), and Indrayani Bhadra (Associate) of TT&A advised on competition law aspects of this deal, reflecting the regulatory complexity of a cross-border investment of this nature that required CCI clearance.
For a broader view of recent legal advisory mandates in Indian M&A and private equity transactions, see our Deal Meter.
The Romsons Temasek investment marks a defining moment in the Indian medical devices sector, bringing one of India’s oldest healthcare manufacturers into a long-term partnership with a global institutional investor. TT&A deployed both a transactional and a competition law team to advise Romsons, while JSA Advocates & Solicitors guided Temasek through the deal. The transaction underscores the growing appetite of sovereign-backed funds for India’s healthcare and medical devices space.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. It is based on the details provided and publicly available sources.
